Company Background:
AI Arrive is an artificial intelligence company with the vision to create AI products that accelerate research and enhance our understanding of human disease. AI Arrive partners with pharmaceutical clients to greatly accelerate R&D and drug development efforts by helping clients to make go/no-go decisions, prioritize drug targets, and uncover the mechanism of action (MoA) for drug targets. DiseaseScribe enables researchers to identify relevant biomedical literature that pertains to their drug’s mechanism of action.

Team Size: 4-5 Students

Location: Remote, client/team meetings will be held with Zoom.

Project Summary: AI Arrive would like to develop a feature of Disease Scribe, a MOA LLM agent that identifies and extracts biomedical abstracts and literature for the Wnt/β-catenin signaling pathway which is one of the most frequently activated pathways in cancer, and ingests the publications into an existing gene-KEGG database. The LLM agent will then extract Wnt/β-catenin inhibitors from the FDA website and relevant publications and identify their mechanism of action (MOA). The team will then be able to visualize the ingested publication on the KEGG network visualization. This will be a tool to help researchers explore publications and the Wnt/β-catenin signaling pathway and relevant therapeutics.

Key Skills/Technologies: A background in LLM agents, AI/ML, NLP, web scrapping and backend (Firebase) would be beneficial for this project. The team can seek guidance from the client.

Student Benefits:
- Freedom to develop a creative solution to the problem.
- Future paid internship opportunities
- Build leadership skills by seeing the project through to completion.
- Opportunity to work on a project that is high impact and can make a difference

Contact Information:
- Dr. Michelle Archuleta, Founder & CEO AI Arrive: marchu0399@gmail.com
  (303)-218-8507